2026-10-13 20:35:00 UTC#454920newconfirmednews
KYNB stock news
KYNB stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire15 wire items
2026-10-01 11:02:00 UTC#397901newconfirmednews
Kyntra Bio Appoints Andrew E. Singer to Board of Directors
2026-10-01 11:00:00 UTC#397975duplicateconfirmedpress release
Kyntra Bio appoints Andrew E. Singer to board, replacing outgoing director Maykin Ho
globenewswireimportance 0.30trust 1.00Kyntra Bio +0.10Andrew E. Singer +0.20Maykin Ho -0.10+1 entities
2026-10-01 11:00:00 UTC#397974duplicateconfirmednews
Kyntra Bio appoints Andrew E. Singer to board, replacing outgoing director Maykin Ho
2026-09-17 13:21:00 UTC#327792newconfirmednews
Kyntra Bio initiated at Buy by Lake Street Capital Markets
2026-09-15 21:24:47 UTC#317042newconfirmednews
Kyntra Bio sets Q4 2024 milestones for FG-3246 prostate cancer and roxadustat MDS clinical trials
2026-09-01 10:36:00 UTC#248216newconfirmednews
H.C. Wainwright & Co. maintains $43.00 price target on Kyntra Bio
2026-08-31 20:05:00 UTC#244913newconfirmedpress release
Kyntra Bio amends royalty financing agreement with NQ Project Phoebus to reduce payment obligations
globenewswireimportance 0.40trust 0.90Kyntra Bio +0.40NQ Project Phoebus, L.P. +0.20Thane Wettig 0+2 entities
2026-08-14 05:28:06 UTC#176079updateconfirmednews
Kyntra Bio targets 10-month median rPFS for FG-3246, confirms Q4 2026 roxadustat Phase III start
2026-08-13 21:59:35 UTC#174903duplicateconfirmednews
Kyntra Bio reports Q2 2026 profitability and clinical progress for FG-3246 and roxadustat
2026-08-13 21:02:21 UTC#174509newconfirmednews
Kyntra Bio Q2 adjusted loss of $4.69/share misses $3.18 loss estimate; revenue of -$1.47M misses $2.01M target
2026-08-13 20:11:26 UTC#174239newconfirmednews
Kyntra Bio Q2 net income $12M on subsidiary deconsolidation; Phase 3 roxadustat trial planned for 4Q 2026
2026-08-07 11:00:34 UTC#144264newforecastnews
Kyntra Bio (KYNB) Q2 2026 Earnings Preview: Analysts Forecast $2.09M Revenue and ($3.18) EPS
2026-08-03 11:00:42 UTC#116386newforecastnews
Kyntra Bio (KYNB) Q2 2026 Earnings Preview: Analysts Forecast $2.09M Revenue and ($3.18) EPS
2026-07-07 09:41:00 UTC#6247newconfirmednews